BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ERAS-0015 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ERAS-0015\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06983743-2476@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:ERAS-0015: Phase 1 readout est. (NCT06983743)
DESCRIPTION:ERAS-0015\, phase 1.\nStudy: A Study of ERAS-0015 in Patients W
 ith Advanced or Metastatic Solid Tumors\nEstimated primary completion: 1 M
 ay 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/eras-0015#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069837
 43
URL:https://assetmemo.bio/drug/eras-0015#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897734-2476@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:ERAS-0015: Phase 1/2 readout est. (NCT07897734)
DESCRIPTION:ERAS-0015\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: TNG
 462-C103: Study to Evaluate the Safety\, Tolerability\, and Antitumor Acti
 vity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patie
 nts\nEstimated primary completion: November 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/eras-0015#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07897734
URL:https://assetmemo.bio/drug/eras-0015#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
